Meth Use Disorder Tackled With Psilocybin: Clinical Trial Begins Patient Enrollment

Life sciences company Revive Therapeutics Ltd. RVVTF’s Phase 1/2 clinical study assessing safety and efficacy of oral psilocybin for the treatment of Methamphetamine Use Disorder (MUD) has enrolled its first subject. 

The investigator-initiated trial led by Dr. Christopher Nicholas at the University of Wisconsin-Madison expects initial results in the third quarter of 2023.

See also: Psychedelics Company Revive Raises $3.2M To Target Infectious Diseases, Disorders

MUD is a chronic relapsing condition associated with substantial mental, physical and social harms and increasing rates of mortality. Usually treated with contingency management and psychotherapy interventions, relapse rates remain high, with pharma treatments proving ineffective as well. 

While psilocybin-assisted therapy is becoming a promising treatment for a range of difficult-to-treat conditions including substance use disorders (SUDs), no other studies seem to have assessed it for MUD treatment to date.

See also: Clinical Site In Alberta Begins Study Of Psychedelic-Assisted Treatment For Alcohol Use Disorder

CEO Michael Frank says the company is committed to advancing novel uses and delivery forms of psilocybin to treat substance abuse and mental health disorders. In this sense, the clinical trial aims to demonstrate psilocybin’s utility for substance abuse indications. 

Furthermore, the study would support future commercial and clinical studies using Revive’s proprietary oral thin film strip and transdermal microneedle patch delivery technologies.

Benzinga’s PCC

The second edition of the Benzinga Psychedelics Capital Conference is inching closer each day! 

The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.

Get your tickets now before prices go up!

Photo: Benzinga edit with photo by DyrElena on Shutterstock and Wikimedia Commons.